U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

On April 28, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5221

Related Post

Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022

Citi Funds $20 Million Loan for ASA Philippines Foundation to Support Women Microentrepreneurs

CNBC|SurveyMonkey Small Business Saturday 2022